newsfilter
← Latest News
GlobeNewswire·

Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • Apnimed granted 10 new non-executive employees non-qualified stock options to purchase 428,428 shares of common stock on August 31, 2026.
  • The exercise price for each option is $26.85 per share, matching the closing trading price on September 1, 2026.
  • Vesting schedules begin one year after the employees' start dates, with equal monthly installments over the subsequent three years contingent on continued employment.
  • The awards were issued as inducement material under Nasdaq Listing Rule 5635(c)(4) pursuant to the Apnimed 2026 Inducement Plan adopted on August 21, 2026.
  • Apnimed is advancing its product candidate AD109 for obstructive sleep apnea (OSA) after completing two Phase 3 clinical trials.
  • The FDA assigned a Prescription Drug User Fee Act goal date of February 28, 2027, for Apnimed's New Drug Application regarding AD109.